FDA extends safety review of mifepristone into next year, report due by March 2027

The FDA announced that its ongoing safety evaluation of mifepristone, the primary medication used for medical abortions, will not be completed until next year.

The agency expects to finish the safety study by mid-December 2026 and will issue a report with its findings no later than March 2027, after which it may consider new restrictions.

Anti-abortion groups quickly criticized the extended timeline, hoping the review could lead to tighter controls on the drug, while the FDA has previously reaffirmed mifepristone's safety since its 2000 approval.